Page 5 - Expanded Access News Today

/PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected...

- Total of six poster presentations analyze the effects of treatment with enzyme replacement therapies in Fabry disease and alpha-mannosidosis -- ...

Continued strong enrollment of pivotal Phase 3 global study evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 on track to complete enrollment by year end 2023 Company anticipates... -Today at 08:13 am- MarketScreener

Donald Trump’s election conspiracy case may be billed as the trial of the century, but as things stand, the public won’t have any way of seeing or hearing it — save for going to the E. Barrett Prettyman United States Courthouse in Washington, D.C., waiting in line and hoping for a seat. Federal criminal courts …

Tiziana Life Sciences, Inc.

Mass. House and Senate finalized the state budget for fiscal 2024, with $150M for regional transit including the Cape Cod Regional Transit Authority.

Cyclo Therapeutics, Inc. , a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today...

Tiziana Life Sciences (NASDAQ: TSLA) has presented data from its clinical trial showing that five of its six patients with an advanced stage of multiple sclerosis (MS) have shown a reduction in microglia activity,

Experts from the International Atomic Energy Agency (IAEA) have asked for expanded access to verify that any explosive devices are absent from the rooftops of reactor buildings at the Russia-occupied Zaporizhzhya Nuclear Power Plant (ZNPP), the agency said in a statement on July 5.

– Data published in official journal of Molecular Genetics and Metabolism Reports: Evidence of a change in cholesterol homeostasis in peripheral organs and the brain after the initial infusion Trappsol® Cyclo™ was detected in the CSF Completers had an 88.9% improvement in at least two domains of the 17-Domain Niemann-Pick Type C1 Clinical Severity Scale (17D-NPC-CSS) Improvement in Scale Assessment and Rating of Ataxia (SARA) score for the mean score in 7 of 8 domains at Week 48 ...